Tessera Launches New Prostate Cancer Test

Tessera, a Seattle-based biomedical company, has released its first product, ProstaMark EPCA (Early Prostate Cancer Antigen), as an analyte specific reagent for commercial use in pathology laboratories to assist pathologists in their efforts to determine if cancer is present in the prostate.

Yahoo News (http://biz.yahoo.com/prnews/050328/sfm026.html?.v=4)